28
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Prognostic Significance of Immunoglobulin and T Cell Receptor Gene Rearrangements in Patients with Acute Myeloid Leukemia: Taiwan Experience

, , , , &
Pages 179-187 | Received 18 Jan 1999, Published online: 01 Jul 2009
 

Abstract

We investigated the prognostic significance of lymphoid antigen receptor gene rearrangement in patients with newly diagnosed acute myeloid leukemia (AML). Thirty-nine patients were included in the study. Clonal gene rearrangement of immunoglobulin heavy chain (IgH) and T cell receptor β chain (TCRβ) was found in leukemic cells in 11 (28.2%) and 10 (25.6%) patients, respectively. Five (12.8%) had both IgH and TCRβ gene rearrangements. Three of the seven (42.9%) B-lymphoid marker-positive and eight of the 32 (25%) B-lymphoid marker-negative patients had clonal IgH gene rearrangements. Five of the 11 (45.5%) T-lym-phoid marker-positive and 5 of the 28 (17.9%) T-lymphoid marker-negative patients had clonal TCRβ gene rearrangements. All patients were treated with similar regimens. The complete remission rate (62.5% vs 65.296, p=1.000) and median survival (13 vs 14 months, p=4.366) were similar in patients with and without clonal IgH or TCRβ gene rearrangements. In conclusion, while clonal rearrangements of IgH or TCRβ genes were found in AML patients, they did not appear to effect the prognosis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.